EGFR+ Lung Cancer | Clinical

Positive Findings From ADAURA Trial Reported, But Questions Remain

December 29, 2020

The early unblinding of results from the phase 3 ADAURA clinical trial evaluating osimertinib, a third-generation EGFR tyrosine kinase inhibitor, was met with much fanfare in the oncology community as details of the interim results spread.

Frontline Regimens Explored for EGFR-Mutated NSCLC

December 20, 2020

During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.

FDA Approves Osimertinib as Adjuvant Therapy for EGFR+ NSCLC

December 18, 2020

The FDA has approved osimertinib as an adjuvant therapy for patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, for use following tumor resection.

New Evidence Supports Targeted Therapies in Early-Stage NSCLC With EGFR Mutations

December 16, 2020

During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.

Trials Demonstrate Which Treatments Physicians Should Use in EGFR+ NSCLC

December 14, 2020

Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.

Phase 3 LAURA Study to Explore Efficacy of Maintenance Osimertinib in Stage III EGFR-Mutant NSCLC

December 14, 2020

The phase 3 LAURA clinical trial is currently enrolling patients with stage III, unresectable EGFR-mutant non–small cell lung cancer to explore the efficacy and safety of the third-generation tyrosine kinase inhibitor osimertinib as maintenance therapy following chemoradiation.